AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth
- PMID: 15208673
- DOI: 10.1038/sj.onc.1207721
AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth
Abstract
Activation of the PI3K/AKT pathway may contribute to tumorigenesis. AKT mediates survival signals that protect cells from apoptosis and, thus, is a potentially important therapeutic target. To determine the frequency of AKT activation in human ovarian cancer, we screened a tumor tissue microarray with a phospho-specific pan-AKT (Ser473) antibody, which revealed elevated staining in 21 of 31 (68%) ovarian carcinomas. Phospho-AKT staining was associated with that of phospho (active)-mTOR in 27 of 31 (87%) ovarian tumors, with 17 (55%) tumors showing elevated phospho-mTOR positivity. We tested the effects of AKT/mTOR activation on the therapeutic sensitivity of ovarian cancer cells. Pretreatment of SKOV3 cells, which exhibit constitutive AKT activity under low serum conditions, with the PI3K inhibitor LY294002 augmented cisplatin-induced apoptosis. In contrast, ovarian cancer cell lines OVCAR4 and OVCAR5, which have low basal levels of AKT activity, did not show increased cisplatin-induced apoptosis when pretreated with LY294002. In addition, inhibition of mTOR activity with rapamycin resulted in G1 arrest in SKOV3 cells, but not in OVCAR4 or OVCAR5 cells. Collectively, these findings indicate that active AKT and downstream mTOR represent potentially important therapeutic and/or chemopreventive targets in ovarian cancer.
Similar articles
-
G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.Am J Physiol Cell Physiol. 2004 Aug;287(2):C281-91. doi: 10.1152/ajpcell.00422.2003. Epub 2004 Mar 17. Am J Physiol Cell Physiol. 2004. PMID: 15028555
-
Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells.Oncogene. 2005 May 19;24(22):3574-82. doi: 10.1038/sj.onc.1208463. Oncogene. 2005. PMID: 15806173
-
Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells.Leuk Res. 2007 May;31(5):673-82. doi: 10.1016/j.leukres.2006.08.001. Epub 2006 Sep 27. Leuk Res. 2007. PMID: 17007924
-
The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.Gynecol Oncol. 2015 Apr;137(1):173-9. doi: 10.1016/j.ygyno.2015.02.003. Epub 2015 Feb 10. Gynecol Oncol. 2015. PMID: 25677064 Review.
-
The Akt-mTOR tango and its relevance to cancer.Cancer Cell. 2005 Sep;8(3):179-83. doi: 10.1016/j.ccr.2005.08.008. Cancer Cell. 2005. PMID: 16169463 Review.
Cited by
-
The Role of Cancer Stem Cell Markers in Ovarian Cancer.Cancers (Basel). 2023 Dec 20;16(1):40. doi: 10.3390/cancers16010040. Cancers (Basel). 2023. PMID: 38201468 Free PMC article. Review.
-
The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges.Chin J Cancer. 2015 Jan;34(1):4-16. doi: 10.5732/cjc.014.10289. Chin J Cancer. 2015. PMID: 25556614 Free PMC article. Review.
-
Ovarian cancer: emerging molecular-targeted therapies.Biologics. 2012;6:147-54. doi: 10.2147/BTT.S24155. Epub 2012 Jun 20. Biologics. 2012. PMID: 22807625 Free PMC article.
-
Targeting the AKT pathway: Repositioning HIV protease inhibitors as radiosensitizers.Indian J Med Res. 2016 Feb;143(2):145-59. doi: 10.4103/0971-5916.180201. Indian J Med Res. 2016. PMID: 27121513 Free PMC article. Review.
-
Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner.J Cell Mol Med. 2011 Jan;15(1):166-78. doi: 10.1111/j.1582-4934.2009.00954.x. J Cell Mol Med. 2011. PMID: 19874425 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous